GC
FBRX icon

Garde Capital’s Forte Biosciences FBRX Stock Holding History

Garde Capital’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,960
Closed -$51.2K – 446
2025
Q2 		$51.2K Hold
3,960
– – ﹤0.01% 346
2025
Q1 		$30.7K Buy
+3,960
New +$46.7K ﹤0.01% 396

Other funds holding FBRX

FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Garde Capital's FBRX Position: Q3 2025 in Review

Garde Capital sold out of Forte Biosciences (FBRX) in Q3 2025, closing a stake of 3,960 shares — an estimated $51.2K sold.

Garde Capital first reported a position in FBRX in Q1 2025 and held it in 2 quarters. The position peaked at $51.2K in Q2 2025. 42 funds tracked by Wall St. Rank hold FBRX as of Q3 2025.

  • Garde Capital reported no remaining Forte Biosciences position as of Q3 2025 after selling out during the quarter.
  • Garde Capital sold 3,960 Forte Biosciences shares in Q3 2025, an estimated $51.2K.
  • Garde Capital first reported a position in Forte Biosciences in Q1 2025 and held it in 2 quarters.
  • Garde Capital's Forte Biosciences position peaked at $51.2K in Q2 2025.
  • 42 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2025.

Based on Garde Capital's 13F filing for Q3 2025, filed 16 Dec 2025.